Shares of ImmuCell Co. (NASDAQ:ICCC) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.86 and traded as low as $5.10. ImmuCell shares last traded at $5.10, with a volume of 100 shares trading hands.
Several equities analysts have commented on the company. ValuEngine upgraded ImmuCell from a “hold” rating to a “buy” rating in a report on Thursday, September 5th. TheStreet downgraded ImmuCell from a “c-” rating to a “d” rating in a report on Wednesday, September 4th.
The company has a current ratio of 6.12, a quick ratio of 4.91 and a debt-to-equity ratio of 0.25. The firm has a fifty day simple moving average of $5.18 and a 200 day simple moving average of $5.86.
Several institutional investors have recently made changes to their positions in the company. Ingalls & Snyder LLC grew its stake in shares of ImmuCell by 5.2% in the second quarter. Ingalls & Snyder LLC now owns 96,243 shares of the biotechnology company’s stock worth $626,000 after acquiring an additional 4,732 shares during the last quarter. Eidelman Virant Capital bought a new position in ImmuCell in the second quarter worth $91,000. Finally, Vanguard Group Inc. lifted its position in ImmuCell by 20.3% in the second quarter. Vanguard Group Inc. now owns 93,954 shares of the biotechnology company’s stock worth $611,000 after purchasing an additional 15,885 shares during the period. Institutional investors and hedge funds own 22.38% of the company’s stock.
ImmuCell Company Profile (NASDAQ:ICCC)
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E.
See Also: Cash Asset Ratio
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.